• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Hereditary Angioedema (HAE) - Pipeline Review, H1 2012 Product Image

Hereditary Angioedema (HAE) - Pipeline Review, H1 2012

  • ID: 2141789
  • May 2012
  • 62 pages
  • Global Markets Direct

Hereditary Angioedema (HAE) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Hereditary Angioedema (HAE) - Pipeline Review, H1 2012', provides an overview of the Hereditary Angioedema (HAE) therapeutic pipeline. This report provides information on the therapeutic development for Hereditary Angioedema (HAE), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE). 'Hereditary Angioedema (HAE) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hereditary Angioedema (HAE).
- A review of the Hereditary Angioedema READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hereditary Angioedema (HAE) Overview
Therapeutics Development
An Overview of Pipeline Products for Hereditary Angioedema (HAE)
Hereditary Angioedema (HAE) Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Hereditary Angioedema (HAE) Therapeutics – Products under Development by Companies
Companies Involved in Hereditary Angioedema (HAE) Therapeutics Development
Pharming Group N.V.
Dyax Corp.
ViroPharma Incorporated
Shire Plc
BioCryst Pharmaceuticals, Inc.
Hereditary Angioedema (HAE) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
RhC1INH - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rhucin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Firazyr - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cinryze - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cinryze - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cinryze + rHuPH20 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BCX4161 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hereditary Angioedema (HAE) Therapeutics – Drug Profile Updates
Hereditary Angioedema (HAE) Therapeutics - Dormant Products
Hereditary Angioedema (HAE) – Product Development Milestones
Featured News & Press Releases
Mar 06, 2012: ViroPharma And Halozyme Report Positive Phase II Trial Data Of Subcutaneous Cinryze With rHuPH20
Feb 29, 2012: ViroPharma's Cinryze Available In UK For Routine Prevention Of Hereditary Angioedema Attacks
Feb 10, 2012: Pharming Initiates Pediatric Phase II Clinical Study With RUCONEST To Treat Hereditary Angioedema
Feb 07, 2012: ViroPharma Provides Update On Industrial Scale Supplement For Cinryze
Jan 13, 2012: Health Canada Grants Priority Review Status For New Drug Submission For ViroPharma's Cinryze
Dec 07, 2011: Santarus And Pharming Announce Oral Presentations Of Retrospective Analyses Of Data From RHUCIN Clinical Program At World Allergy Congress
Dec 06, 2011: ViroPharma And Halozyme Therapeutics Announce Positive Data From Initial Phase II Assessment Of Subcutaneous Cinryze With Hyaluronidase
Nov 04, 2011: Santarus And Pharming Announce Presentation Of Retrospective Analyses Of Data From Clinical Studies Of RHUCIN
Sep 13, 2011: ViroPharma And Halozyme Therapeutics Announce Initiation Of Phase II Evaluation Of Subcutaneous Delivery Of Cinryze With Hyaluronidase
Sep 12, 2011: BioRx Expands Therapy Offering To Patients With Hereditary Angioedema
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Hereditary Angioedema (HAE), H1 2012
Products under Development for Hereditary Angioedema (HAE) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Pharming Group N.V., H1 2012
Dyax Corp., H1 2012
ViroPharma Incorporated, H1 2012
Shire Plc, H1 2012
BioCryst Pharmaceuticals, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Hereditary Angioedema (HAE) Therapeutics – Drug Profile Updates
Hereditary Angioedema (HAE) Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Hereditary Angioedema (HAE), H1 2012
Products under Development for Hereditary Angioedema (HAE) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos